Avalo Therapeutics (AVTX) Cash & Equivalents (2014 - 2026)
Avalo Therapeutics posted quarterly Cash & Equivalents of $147000.0 for Q1 2026, down 99.88% year-on-year from $125.0 million in Q1 2025, and up 297.3% on a QoQ basis from $37000.0 in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Cash & Equivalents data on file, last reported at $147000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents fell 99.88% year-over-year to $147000.0; the trailing twelve-month figure through Mar 2026 stood at $147000.0 (down 99.88% YoY), and the FY2025 full-year result was $37000.0, down 99.97% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $147000.0, up from $37000.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $134.5 million in Q4 2024 and bottomed at $1000.0 in Q3 2023.
- The 5-year median for Cash & Equivalents is $100000.0 (2022), against an average of $34.1 million.
- The widest annual swing landed in 2023, when Cash & Equivalents sank 99.99%; it then surged 13454500.0% in 2024.
- A 5-year view of Cash & Equivalents shows it stood at $15000.0 in 2022, then tumbled by 93.33% to $1000.0 in 2023, then soared by 13454500.0% to $134.5 million in 2024, then plunged by 99.97% to $37000.0 in 2025, then surged by 297.3% to $147000.0 in 2026.
- The last three Cash & Equivalents figures came in at $147000.0 (Q1 2026), $37000.0 (Q4 2025), and $90000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | 37,000.00 |
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 125.05 Mn |
| Dec 31, 2024 | 134.55 Mn |
| Sep 30, 2024 | 81.86 Mn |
| Jun 30, 2024 | 93.43 Mn |
| Mar 31, 2024 | 110.18 Mn |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Mar 31, 2023 | 16.69 Mn |
| Dec 31, 2022 | 15,000.00 |
| Sep 30, 2022 | 16.94 Mn |
| Jun 30, 2022 | 14,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 54.59 Mn |
| Sep 30, 2021 | 71.51 Mn |
| Jun 30, 2021 | 40.44 Mn |
| Mar 31, 2021 | 38.29 Mn |
| Dec 31, 2020 | 38,000.00 |
| Sep 30, 2020 | 132,000.00 |
| Jun 30, 2020 | 33,000.00 |
| Mar 31, 2020 | 65,000.00 |
| Dec 31, 2019 | 17,535.00 |
| Sep 30, 2019 | 102,214.00 |
| Jun 30, 2019 | 9.39 Mn |
| Mar 31, 2019 | 16.12 Mn |
| Dec 31, 2018 | 18,730.00 |
| Sep 30, 2018 | 37,027.00 |
| Jun 30, 2018 | 2.18 Mn |
| Mar 31, 2018 | 2.52 Mn |
| Dec 31, 2017 | 2.61 Mn |
| Sep 30, 2017 | 23.96 Mn |
| Jun 30, 2017 | 13,300.00 |
| Mar 31, 2017 | 3.00 Mn |
| Dec 31, 2016 | 5.20 Mn |
| Sep 30, 2016 | 8.82 Mn |
| Jun 30, 2016 | 11.88 Mn |
| Mar 31, 2016 | 16.60 Mn |
| Dec 31, 2015 | 21.16 Mn |
| Sep 30, 2015 | 3.31 Mn |
| Jun 30, 2015 | 6.14 Mn |
| Mar 31, 2015 | 8.66 Mn |
| Dec 31, 2014 | 11.74 Mn |
| Sep 30, 2014 | 15.73 Mn |